Details for New Drug Application (NDA): 213953
✉ Email this page to a colleague
NDA 213953 describes KYZATREX, which is a drug marketed by Marius and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the KYZATREX profile page.
The generic ingredient in KYZATREX is testosterone undecanoate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.
The generic ingredient in KYZATREX is testosterone undecanoate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.
Summary for 213953
| Tradename: | KYZATREX |
| Applicant: | Marius |
| Ingredient: | testosterone undecanoate |
| Patents: | 6 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 213953
Generic Entry Date for 213953*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 213953
| Mechanism of Action | Androgen Receptor Agonists |
Suppliers and Packaging for NDA: 213953
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| KYZATREX | testosterone undecanoate | CAPSULE;ORAL | 213953 | NDA | Marius Pharmaceuticals | 80603-103 | 80603-103-11 | 90 CAPSULE, LIQUID FILLED in 1 BOTTLE (80603-103-11) |
| KYZATREX | testosterone undecanoate | CAPSULE;ORAL | 213953 | NDA | Marius Pharmaceuticals | 80603-103 | 80603-103-22 | 120 CAPSULE, LIQUID FILLED in 1 BOTTLE (80603-103-22) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 100MG | ||||
| Approval Date: | Jul 27, 2022 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Dec 31, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | METHOD OF TREATING TESTOSTERONE DEFICIENCY | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Dec 31, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Start Trial | Patent Expiration: | Dec 31, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
